Coercive Control and Intimate Partner Violence (NCT07578194) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Coercive Control and Intimate Partner Violence
France250 participantsStarted 2026-05-30
Plain-language summary
Coercive control (CC) is increasingly recognized as a central component of intimate partner violence (IPV) and a major determinant of victims' health outcomes. While widely integrated into policy and legal frameworks in several countries, CC remains insufficiently explored in the French research context, particularly regarding its clinical and psychopathological dimensions. This gap may limit the identification of victims and the provision of appropriate care.
The present study aims to investigate the association between exposure to coercive control and physical and mental health outcomes among victims of intimate partner violence. By improving the understanding of CC-related health impacts, this research seeks to support better identification of high-risk situations and inform clinical and public health interventions.
Who can participate
Age range
18 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Women aged 18 years and older, who have experienced an intimate partner relationship involving violence for at least three months (currently in the relationship or separated).
* Women identified as victims of intimate partner violence.
* Sufficient proficiency in French to complete self-administered questionnaires and participate in interviews.
* No objection to participation in the study (non-opposition).
* Affiliation with a French social security scheme or eligibility for universal health coverage (Couverture Maladie Universelle, CMU).
Exclusion Criteria:
* Individuals under legal protection in accordance with the French Public Health Code (Articles L.1121-5 to L.1121-8 and L.1122-1-2), with the exception of pregnant or breastfeeding women.
* Cognitive impairment or severe intellectual disability preventing comprehension of the questionnaires.
* Severe and unstable psychiatric disorders (e.g., schizophrenia, delusional disorders, acute bipolar disorder).
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Coercive Control Screening Scale
Timeframe: Measure of CCSS between inlusion and month 6
Trial details
NCT IDNCT07578194
SponsorCentre Hospitalier Intercommunal Robert Ballanger